Search
Philip Ponce, MD, Infectious Diseases, was quoted in this story. Read More
Kevin Bieniek, PhD, Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, is quoted in this article. Read More
An evergreen tree was lifted to the roof of the new primary, specialty and surgery center recently – signaling the construction of UT Health San Antonio at Kyle Seale Parkway has reached its final height. The topping out of a new building is a Scandinavian tradition dating back more than thirteen centuries. The five-story, 108,000-square-foot […]
Metformin, SGLT-2 inhibitors and insulin resistance among career highlights Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Nov. 29, 2022) — Ralph A. DeFronzo, MD, professor of medicine at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and deputy director of University Health’s Texas Diabetes Institute, will receive one of […]
Elacestrant may improve care of metastatic ER+/HER2- tumors Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Nov. 30, 2022) — Phase III results of EMERALD, a clinical trial evaluating a novel oral drug therapy for metastatic ER-positive/HER2-negative (ER+/HER2-) breast cancer, will be presented Thursday, Dec. 8, at the San Antonio Breast Cancer Symposium (SABCS). Virginia…
Tess Barton, MD, Pediatrics, is quoted in this Q&A. Read More
Jason Rosenfeld, Center for Medical Humanities and Ethics, is quoted in this article. Read More
Melanie Stone, MPH, MEd, assistant director of community service learning wrote this op-ed piece for the San Antonio Express-News. Read More
Four-year, $2 million federal grant will more than double rural providers Contact: Steven Lee, 210-450-3823, lees22@uthscsa.edu SAN ANTONIO, Dec. 1, 2022 – UT Health San Antonio has received a four-year, $2 million federal grant to expand its substance use disorder response program, Be Well Texas, to the state’s 178 rural counties that have limited or […]
The AHEAD clinical trial will assess whether the new Alzheimer’s drug, lecanemab, can delay the onset of dementia in persons who are at high risk of developing the disease. Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (Dec. 1, 2022) — The Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, part of The University of Texas […]